EGFR and non-small cell lung carcinoma: Furthermore, abnormal activation of the PI3K-AKT-mTOR pathway has been proved to generate acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in NSCLC [1].